Ameet Mallik is the Chief Executive Officer at ADC Therapeutics SA, a position he has held since 2016. With a robust background in the biopharmaceutical industry, Mallik has been instrumental in guiding ADC Therapeutics through significant growth and development phases. Before joining ADC Therapeutics, he served as the Chief Executive Officer at Cell Therapeutics, Inc., where he played a pivotal role in transforming the company into a global oncology enterprise. His leadership at Cell Therapeutics culminated in the successful acquisition of the company by Servier Pharmaceuticals in 2015. Mallik's career is marked by his strategic vision and ability to drive innovation in the oncology sector. He holds an MBA from Columbia Business School and a Bachelor of Science in Chemical Engineering from the Massachusetts Institute of Technology (MIT). His educational background has equipped him with a strong foundation in both business and technical aspects of pharmaceuticals, enabling him to lead ADC Therapeutics effectively. Under his leadership, ADC Therapeutics has advanced its pipeline of antibody-drug conjugates (ADCs), with a focus on developing novel therapies for patients with hematologic malignancies and solid tumors. As CEO of ADC Therapeutics, Ameet Mallik is responsible for overseeing the company's overall strategy and operations. His role involves steering the company towards its mission of delivering transformative cancer treatments, fostering a culture of innovation, and ensuring the successful clinical development and commercialization of its products. Mallik's leadership has been crucial in securing partnerships and collaborations that have bolstered the company's research and development efforts. His dedication to advancing cancer care continues to drive ADC Therapeutics forward as it seeks to make a meaningful impact on the lives of patients worldwide.